Quantcast
Last updated on April 16, 2014 at 14:05 EDT

Latest Genentech Stories

Promising Results From Pilot Study For AMD
2013-06-18 13:40:01

University of Iowa There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, “wet” stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two...

2013-06-11 08:30:26

INCLINE VILLAGE, Nev., June 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that on June 7, 2013, the Company filed a Notice of Arbitration against Genentech with the American Arbitration Association in Voorhees, New Jersey, alleging, inter alia, that Genentech underpaid royalties going back to at least 2007 and impeded PDL's attempts to have Genentech's books and records inspected to determine whether Genentech's past payments to PDL were accurately...

2013-05-29 08:28:06

Lucentis's Prescriber Base and Patient Share Have Grown But Cost-Related Obstacles Remain, According to a New Report from BioTrends Research Group EXTON, Pa., May 29, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, despite the approval of Genentech's Lucentis 0.3 mg in August 2012 as the first intravitreal therapy (IVT) for the treatment of diabetic macular edema (DME),...

2013-05-15 12:33:06

PENZBERG, Germany, May 15, 2013 /PRNewswire/ -- Researchers from academia throughout Europe are invited to participate In a newly created award, pRED`s Discovery Oncology unit of Roche (SIX: RO, ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to submit abstracts which describe their scientific work in the field of tumor-selective membrane targets for antibody-based cancer therapy. The award aims to honor and support outstanding research in the...

2013-04-25 08:35:22

Genentech Ranks Highest in Physician Satisfaction with Biopharmaceutical Manufacturers WESTLAKE VILLAGE, Calif., April 25, 2013 /PRNewswire/ -- Although the role of pharmaceutical sales representatives has changed in recent years, physicians continue to perceive the sales representative as the leading influence on their relationship with biopharmaceutical companies, according to the J.D. Power and Associates 2013 Physician Manufacturer Experience Study--Oncology(SM )released today....

2013-04-09 08:31:40

Surveyed Payers Expect to Restrict the Prescribing of Emerging Biologics Through Controls Similar to Xolair, Limiting Patient Access, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with...

2013-03-28 16:24:33

ReportsnReports.com offers 2013 market research reports on polymer biomaterials and protein engineering industry products like monoclonal antibodies, insulin analog and modified EPO. DALLAS, March 28, 2013 /PRNewswire-iReach/ -- Market Research on Biomaterials and Protein Engineering Industry Products with Technology and Applications (Photo: http://photos.prnewswire.com/prnh/20130328/CG85250) The global biomaterials market is poised to grow at a CAGR of 15% from 2012 to 2017 to...

2013-03-11 08:26:59

INCLINE VILLAGE, Nev., March 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in royalty revenues is driven by increased fourth quarter 2012 sales for all licensed...

2013-03-06 16:29:15

MENLO PARK, Calif., March 6, 2013 /PRNewswire/ -- Facebook announced today that Susan Desmond-Hellmann, M.D., M.P.H., chancellor of the University of California, San Francisco (UCSF), has been elected to the company's board of directors. "Sue has a great track record of building and managing a diverse set of organizations, so her insights will be valuable as we continue to expand into new areas," said Mark Zuckerberg, founder and CEO of Facebook. "Her experience shaping public policy and...

2013-03-01 16:25:17

INCLINE VILLAGE, Nev., March 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Total revenues in 2012 were $374.5 million, compared to $362.0 million in 2011, with royalty revenues increasing seven percent over full year 2011. For the fourth quarter of 2012, total revenues were $86.0 million, compared to...